BLISOVI FE 1.5/30 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Blisovi Fe 1.5/30, and when can generic versions of Blisovi Fe 1.5/30 launch?
Blisovi Fe 1.5/30 is a drug marketed by Lupin Ltd and is included in one NDA.
The generic ingredient in BLISOVI FE 1.5/30 is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
Summary for BLISOVI FE 1.5/30
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | BLISOVI FE 1.5/30 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for BLISOVI FE 1.5/30
US Patents and Regulatory Information for BLISOVI FE 1.5/30
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lupin Ltd | BLISOVI FE 1.5/30 | ethinyl estradiol; norethindrone acetate | TABLET;ORAL-28 | 201585-001 | Nov 18, 2015 | BX | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
